The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of SF3B1 mutation on outcomes in myelofibrosis.
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; CTI BioPharma Corp; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia
Consulting or Advisory Role - Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Incyte (Inst); Kartos Therapeutics (Inst); NS Pharma (Inst); Promedior (Inst)
 
Jayastu Senapati
No Relationships to Disclose
 
Lucia Masarova
No Relationships to Disclose
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Honoraria - Abbvie; Aptitude Health; Blueprint Medicines; CareDX; Celgene; DAVA Pharmaceuticals; Incyte; LFB Biotechnologies; MustangBio; NeoPharm; Novartis; Roche Molecular Diagnostics; Springer; Stemline Therapeutics
Consulting or Advisory Role - Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; Clearview Healthcare Partners; CTI BioPharma Corp; Immunogen; Pacylex; Protagonist Therapeutics; Triptych Health Partners
Research Funding - Abbvie; Affymetrix/Thermo Fisher Scientific; Cellectis; Daiichi Sankyo; MustangBio; Novartis; Plexxikon; Samus Therapeutics; Stemline Therapeutics
Travel, Accommodations, Expenses - Abbvie; Celgene; DAVA Oncology; MustangBio; Stemline Therapeutics
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Guillermo Montalban Bravo
Research Funding - IFM Therapeutics (Inst)
 
Sherry Pierce
No Relationships to Disclose
 
Lingsha Zhou
No Relationships to Disclose
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Sierra Oncology
Research Funding - AbbVie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Galecto (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); PharmaEssentia (Inst); Protagonist Therapeutics (Inst); Sierra Oncology (Inst); Telios (Inst)